| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 |
|---|---|---|---|---|---|---|---|---|---|---|
Operating activities: | ||||||||||
Net loss | ||||||||||
-204,749 | -178,840 | -197,484 | -173,143 | -97,591 | -76,367 | -55,283 | -23,348 | -11,814 | -7,346 | -10,028 |
Adjustments to reconcile net loss to net cash used for operating activities: | ||||||||||
Stock-based compensation expense | ||||||||||
51,411 | 33,367 | 30,538 | 25,956 | 14,360 | 8,067 | 10,890 | 5,732 | 1,890 | 1,749 | 1,137 |
Depreciation and amortization | ||||||||||
2,000 | 1,500 | 1,500 | 1,099 | 734 | 578 | 333 | 197 | 179 | 227 | 356 |
Loss from discontinued operations | ||||||||||
- | - | - | - | - | - | - | - | - | -150 | 68 |
Amortization of debt discount | ||||||||||
1,050 | 890 | 773 | 689 | 624 | 573 | 533 | 389 | 103 | 0 | 0 |
Realized gain on available-for-sale securities | ||||||||||
8 | 0 | 0 | - | - | - | - | - | - | - | - |
Accretion of discount on short-term investments | ||||||||||
3,730 | 3,412 | 278 | -274 | -89 | 0 | 0 | - | - | - | - |
Gain from discontinued operations | ||||||||||
- | - | - | - | - | - | - | 1,082 | -379 | - | - |
Impairment of property and equipment | ||||||||||
107 | 72 | - | - | - | 905 | 0 | - | - | - | - |
Loss on disposal of property and equipment | ||||||||||
-62 | -29 | -39 | -9 | 118 | -17 | 0 | - | - | - | - |
Loss on retirement of fixed assets | ||||||||||
- | - | - | - | - | - | - | - | - | 4 | 17 |
Stock issued in lieu of bonus | ||||||||||
- | - | - | - | - | - | - | - | - | - | 36 |
Change in operating assets and liabilities: | ||||||||||
Accounts receivable | ||||||||||
-24,773 | 22,778 | 39,914 | 1,960 | 0 | 0 | - | - | -110 | 61 | -139 |
Prepaid expenses and other assets | ||||||||||
12,052 | 7,482 | -3 | 338 | 2,443 | 419 | 54 | 318 | -16 | 267 | -303 |
Inventory | ||||||||||
-14,064 | 29,122 | 4,768 | 5,340 | 0 | 0 | - | - | - | - | - |
Other long-term assets | ||||||||||
- | - | - | - | - | - | - | - | 77 | 75 | -25 |
Accounts payable | ||||||||||
-14,105 | -1,906 | 11,955 | 3,514 | 751 | 1,285 | -426 | 984 | 467 | -3 | -182 |
Accrued clinical and manufacturing liabilities | ||||||||||
10,144 | -3,614 | 13,713 | 7,976 | 1,420 | 2,038 | 1,127 | 92 | - | - | - |
Accrued payroll and employee liabilities | ||||||||||
1,851 | 4,537 | 446 | 3,586 | 2,097 | 165 | 2,153 | -149 | - | - | - |
Deferred revenue | ||||||||||
- | - | 1,664 | 1,099 | 0 | 0 | - | - | -272 | -88 | -640 |
Other accrued liabilities | ||||||||||
4,558 | 14,941 | 11,482 | 2,482 | 1,551 | 2,876 | -36 | 494 | - | - | - |
Accrued expenses | ||||||||||
- | - | - | - | - | - | - | - | 1,298 | -579 | -1,160 |
Net cash used for operating activities | ||||||||||
- | - | - | - | - | - | - | - | - | -5,483 | -10,999 |
Net cash provided by discontinued operations | ||||||||||
- | - | - | - | - | - | - | - | - | 0 | 0 |
Net cash used for operating activities | ||||||||||
-124,580 | -191,805 | -170,300 | -134,097 | -78,526 | -60,282 | -40,763 | -17,009 | -7,721 | -5,483 | -10,999 |
Investing activities: | ||||||||||
Purchases of short-term investments | ||||||||||
477,035 | 497,104 | 121,570 | 43,318 | 56,115 | 0 | 0 | - | - | - | - |
Maturities and sales of short-term investments | ||||||||||
462,406 | 227,700 | 131,783 | 61,329 | 0 | 0 | - | - | - | - | - |
Purchases of property and equipment | ||||||||||
7,154 | 9,171 | 2,553 | 3,135 | 1,086 | 1,438 | 1,685 | 972 | 513 | 78 | 2 |
Proceeds from the sale of property and equipment | ||||||||||
- | 25 | 78 | - | 241 | 0 | 0 | - | - | - | - |
Maturities of marketable securities | ||||||||||
- | - | - | - | - | - | - | - | - | - | 614 |
Net cash provided by investing activities | ||||||||||
-21,783 | -278,550 | 7,738 | 14,876 | -56,960 | -1,438 | -1,685 | -972 | -513 | -78 | 612 |
Net proceeds from sale of common stock and/or pre-funded warrants | ||||||||||
162,151 | 363,128 | 306,279 | - | 128,199 | 58,916 | 57,802 | 50,491 | 22,772 | - | - |
Proceeds from purchases under the Employee Stock Purchase Plan | ||||||||||
2,109 | 1,179 | 989 | 771 | 257 | 91 | 34 | 22 | 15 | 30 | 42 |
Proceeds from convertible note financing, net of issuance costs | ||||||||||
- | - | - | - | - | - | - | - | - | - | 0 |
Proceeds from stock option exercises | ||||||||||
22,164 | 18,301 | 11,463 | 6,684 | 9,535 | 3,101 | 2,793 | - | 0 | 47 | 20 |
Proceeds from issuance of promissory note payable to related party | ||||||||||
- | - | - | 50,000 | 0 | 0 | - | - | - | - | - |
Proceeds from warrant exercises | ||||||||||
1 | - | - | - | - | - | 600 | - | - | - | - |
Repayment of promissory note payable to related party | ||||||||||
- | 25,000 | 25,000 | - | 0 | - | - | - | - | - | - |
Proceeds from sale of common stock, net of issuance costs | ||||||||||
- | - | - | - | - | - | - | - | - | 0 | - |
Proceeds from sale of units of common stock and warrants, net of issuance costs | ||||||||||
- | - | - | - | - | - | - | - | - | 0 | 7,951 |
Net proceeds from convertible note financing | ||||||||||
- | - | - | - | - | - | - | 3,000 | 1,312 | 0 | - |
Net cash provided by financing activities | ||||||||||
186,425 | 357,608 | 293,731 | 57,455 | 137,991 | 62,108 | 61,229 | 53,513 | 24,099 | 77 | 8,013 |
Net increase (decrease) in cash and cash equivalents | ||||||||||
40,062 | -112,747 | 131,169 | -61,766 | 2,505 | 388 | 18,781 | 35,532 | 15,865 | -5,484 | -2,374 |
Supplemental disclosure of cash flow information: | ||||||||||
Interest paid | ||||||||||
- | 1,183 | 2,789 | 1,622 | 0 | 0 | 0 | 0 | 2 | 4 | 4 |
Cumulative effect of adoption of new accounting standard | ||||||||||
- | 1,574 | - | - | - | - | - | - | - | - | - |